Congratulations to group member Simon Finnegan who has co-authored an article in the journal ‘Advances in Woundcare’ with Scapa Healthcare collaborator Steven Percival. The article ‘EDTA: An Antimicrobial and Antibiofilm Agent for Use in Wound Care’ is available online ahead of its print date this November.
Significance: Methods employed for preventing and eliminating biofilms are limited in their efficacy on mature biofilms. Despite this a number of antibiofilm formulations and technologies incorporating ethylenediaminetetraacetic acid (EDTA) have demonstrated efficacy on in vitro biofilms. The aim of this article is to critically review EDTA, in particular tetrasodium EDTA (tEDTA), as a potential antimicrobial and antibiofilm agent, in its own right, for use in skin and wound care. EDTA’s synergism with other antimicrobials and surfactants will also be discussed.
Recent Advances: The use of EDTA as a potentiating and sensitizing agent is not a new concept. However, currently the application of EDTA, specifically tEDTA as a stand-alone antimicrobial and antibiofilm agent, and its synergistic combination with other antimicrobials to make a “multi-pronged” approach to biofilm control is being explored.
Critical Issues: As pathogenic biofilms in the wound increase infection risk, tEDTA could be considered as a potential “stand-alone” antimicrobial/antibiofilm agent or in combination with other antimicrobials, for use in both the prevention and treatment of biofilms found within abiotic (the wound dressing) and biotic (wound bed) environments. The ability of EDTA to chelate and potentiate the cell walls of bacteria and destabilize biofilms by sequestering calcium, magnesium, zinc, and iron makes it a suitable agent for use in the management of biofilms.
Future Direction: tEDTA’s excellent inherent antimicrobial and antibiofilm activity and proven synergistic and permeating ability results in a very beneficial agent, which could be used for the development of future antibiofilm technologies.
The article is available here.